Navigation Links
Oncology is the Most Active Therapeutic Area for Phase II/III R&D
Date:11/21/2013

BURLINGTON, Mass., Nov. 21, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while metabolic drugs account for one-quarter of drugs recently filed for approval or approved, oncology continues to be the most active therapeutic area for Phase II and III research and development (R&D). Among the top 25 biopharmaceutical companies, oncology is the focus for 30 percent of Phase II drugs and 22 percent of Phase III drugs. According to Decision Resources' Strategic Insights report entitled R&D Trends: Will Pharma's Investment Deliver?, other active therapeutic areas of R&D include obesity drugs, anti-diabetics, anti-infectives, central nervous system drugs, musculoskeletal/pain drugs and respiratory drugs.

The analysis also reveals that despite enduring multiple failures in 2011 and 2012 with drugs in Phase III development, Novartis is poised to benefit from a rich Phase III pipeline. Decision Resources expects Novartis will replace Pfizer as the top global biopharmaceutical company in 2015.

"To maximize R&D investments, biopharmaceutical companies must continue to address Phase II and III attrition and identify better prospects early on," said Decision Resources Group Senior Vice President Kate Hohenberg. "As more than half of the costs associated with new drugs are accrued from Phase II on, this could lead to significant cost savings."

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company. <
'/>"/>

SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genelux, a Leader in the Emerging Oncolytic Virotherapy Field, Receives Significant Industry Honor from Elsevier Business Intelligence, Identifying GL-ONC1 as One of 2013s Top Oncology Projects to Watch
2. QIAGEN Announces Partnership With Clovis Oncology to Co-develop Companion Diagnostic Targeting Drug-Resistant EGFR Mutations
3. In The Face Of Increasing Healthcare Spend And High-Cost Targeted Treatment, Market Access Barriers Continue To Rise For Targeted Oncology Drugs
4. Elekta Opens Global Education Center for Oncology and Neuroscience Professionals
5. Enhanced Strategies for Design and Execution of Biomarker-driven Oncology Trials, new life science webinar hosted by Xtalks
6. Cancer Patients to See More Precise Oncology Treatment via Innovative Life Sciences Coalition
7. Oncology Therapeutics Market in India to 2018 Report
8. Vermillions OVA1 Receives New Statement by Society of Gynecologic Oncology
9. Closed Drug Transfer Systems: Oncology Therapeutics Market Dynamics and Closed Drug Transfer Design Factors - Market Forecasts to 2017
10. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
11. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Glenn Keet, CEO of Clinovo , ... Clinical Data Integration with EDC Systems ” at the ... on June 14th-18th. , During the presentation, Glenn Keet ... EDC, and will examine the value of patient engagement, ... health records/electronic medical records integration. , The presentation ...
(Date:5/28/2015)... MN (PRWEB) May 28, 2015 ... it a point to ask his audiences if ... future trends including robotics, solar cells, fuel cells, ... 3D printers, advanced battery storage technology, driverless cars, ... and high-quality but inexpensive online education. , ...
(Date:5/28/2015)... Virginia (PRWEB) May 28, 2015 ... LLC announced today that Roger L. Williams, MD, ... consultant. NDA Partners Premier Experts are top tier ... to bring extraordinary value to the company’s clients. ... solutions to help clients successfully develop their medical ...
(Date:5/28/2015)... Clinerion, an eClinical technology ... the Alliance for Clinical Research Excellence and ... operating in the public interest and dedicated ... quality, safety, integrity and operational effectiveness in ... pleased to announce their partnership for accelerating ...
Breaking Biology Technology:Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2Futurist Jack Uldrich to Deliver 4 Keynote Addresses in June 2Former CEO and Chair of the Council of Experts at the USP, Roger L. Williams, MD, Joins NDA Partners as a Premier Expert Consultant 2Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 2Clinerion and ACRES Partner on Patient Recruitment and Risk-Based Quality Management 3
... Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ: ONCY ) ... its U.K. clinical trial to evaluate the anti-tumour ... with gemcitabine (Gemzar(R)) in patients with advanced cancers ... investigators are Dr. Johann de Bono of The ...
... technologyWASHINGTON, March 24 The safety of early ... by the existing regulatory framework for biotechnology, especially ... advances in this emerging field are likely to ... to a new report authored by Michael Rodemeyer ...
... - Strong Growth in Results Sales up 16%, net Profit up 17%, - Sound Financial Position, - Proposed Increase ... financial statements: , , EUR millions ... ... as % of %, ...
Cached Biology Technology:Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 2Oncolytics Biotech(R) Inc. Completes Enrolment in Combination REOLYSIN(R)/Gemcitabine Trial 3Synthetic Biology: The Next Biotech Revolution Is Brewing 2Synthetic Biology: The Next Biotech Revolution Is Brewing 3STALLERGENES: 2008: Strong Performance 2STALLERGENES: 2008: Strong Performance 3
(Date:5/18/2015)... Fingerprint Cards (FPC) has received an order for ... from one if its module partners. Deliveries are planned to ... the sensors will be used by smartphone manufacturers in ... amount to 740 MSEK to date. In addition to previously ... number of smaller orders not separately communicated amounting to more ...
(Date:5/11/2015)...  Through a well-rounded UAS delegation representing private industry, government, ... showing at AUVSI,s Unmanned 2015 conference last week in ... UAS industry met with over 200 hundred people ... the UAS ecosystem. "Our message is clear ... Aerospace Rich Knoll . "If you want to fly ...
(Date:5/7/2015)... Sweden , May 7, 2015 ... touch fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest ... and FPC1035 are mainly considered for integration on ... size gives smartphone OEMs increased possibilities to integrate ... The decreased size also improves possibilities for module ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... Between 20 and 30 percent of women who undergo ... depression. Many practitioners believe that the hormone therapy involved in ... from Tel Aviv University shows that, while this is true, ... to Dr. Miki Bloch of Tel Aviv University,s Sackler Faculty ...
... This release is available in German . ... and Neanderthals is the subject of contentious disputes in ... modern humans and Neanderthals overlap, many researchers previously assumed ... similar. Among humans, however, the internal organization of the ...
... New Rochelle, NY, November 9, 2010The link between ... Syndrome (SIDS) may relate to the negative effects of ... breathing, according to an article in the recent issue ... peer-reviewed journal published by Mary Ann Liebert, Inc. ( ...
Cached Biology News:Overcoming the IVF baby blues 2Overcoming the IVF baby blues 3The brains of Neanderthals and modern humans developed differently 2The brains of Neanderthals and modern humans developed differently 3The brains of Neanderthals and modern humans developed differently 4New report suggests why risk for sudden infant death syndrome is greater in babies of mothers who smoke 2
Matrix for protein MALDI-MS...
Originally developed for the culture of Drosophila; suitable for culture of other dipteran cell lines. Powder, Insect cell culture tested...
... number is a new product ... Cornings product number. If showing ... under the old Sigma-Aldrich number ... for assistance. Mfr Desig: ...
Collected from calves that are 10 days old or less. Sterile, cell culture tested, US Origin...
Biology Products: